Table 1.
Randomized-controlled trials for the first-line non-bismuth containing quadruple therapies
| Author | Country | Publication year | Therapy regimen | Patients (n) | Eradication rate (ITT) | |
| Wu et al[35] | Taiwan | 2010 | S | E 40 mg bd + AMX 1 g bd for 5 d followed by | 115 | 92.3% |
| E 40 mg bd + CLA 500 mg bd + MET 500 mg bd for 5 d | ||||||
| C | E 40 mg bd + AMX 1 g bd + CLA 500 mg bd + MET 500 mg bd for 10 d | 117 | 93.0% | |||
| Huang et al[38] | Taiwan | 2012 | S | L 30 mg bd + AMX 1 g bd for 5 d followed by | 85 | 80.0% |
| L 30 mg bd + CLA 500 mg bd +MET 500 mg bd for 5 d | ||||||
| C | L 30 mg bd + AMX 1 g bd + CLA 500 mg bd + MET 500 mg bd for 10 d | 84 | 88.1% | |||
| McNicholl et al[39] | Spain | 2013 | S | O 20 mg bd + AMX 1 g bd for first 5 d followed by | 170 | 81% |
| O 20 mg bd + CLA 500 mg bd + MET 500 mg bd for 5 d | ||||||
| C | O 20 mg bd + AMX 1 g bd + CLA 500 mg bd + MET 500 mg bd for 10 d | 168 | 87% | |||
| Lim et al[40] | Korea | 2013 | S | R 20 mg bd + AMX 1 g for 7 d followed by | 86 | 75.6% |
| R 20 mg bd + CLA 500 mg bd + MET 500 mg bd for 7 d | ||||||
| C | R 20 mg bd + AMX 1 g bd + CLA 500 mg bd + MET 500 mg bd for 14 d | 78 | 80.8% | |||
| Zullo et al[41] | Italy | 2013 | S | O 20 mg qd + AMX 1 g qd 5d followed by | 90 | 91.1% |
| O 20 mg qd + CLA 500 mg qd + TIN 500 mg qd for 5 d | ||||||
| C | O 20 mg qd + AMX 1 g qd + CLA 500 mg qd + TIN 500 mg qd for 5 d | 90 | 85.5% | |||
| H | O 20 mg qd + AMX 1 g qd for 14 d plus | 90 | 80.0% | |||
| CLA 500 mg qd + TIN 500 mg qd for last 7 d | ||||||
| Sardarian et al[42] | Iran | 2013 | S | P 40 mg bd + AMX 1 g bd for 5 d followed by | 210 | 76.7% |
| P 40 mg bd + CLA 500 mg bd + TIN 500 mg bd for 5 d | ||||||
| H | P 40 mg bd + AMX 1 g bd for 14 d plus | 210 | 89.5% | |||
| CLA 500 mg bd + TIN 500 mg bd for last 7 d | ||||||
| Molina-Infante et al[37] | Spain, Italy | 2013 | C | O 40 mg bd + AMX 1 g bd + CLA 500 mg bd + NIT 500 mg bd for 14 d | 172 | 91.7% |
| H | O 40 mg bd + AMX 1 g bd for 14 d plus | 171 | 90.0% | |||
| CLA 500 mg bd + TIN 500 mg bd for last 7 d | ||||||
ITT: Intention-to-treat; S: Sequential therapy; C: Concomitant therapy; H: Hybrid therapy; AMX: Amoxicillin; CLA: Clarithromycin; MET: Metronidazole; TIN: Tinidazole; E: Esomeprazole; L: Lansoprazole; P: Pantoprazole; O: Omeprazole; R: Rabeprazole; bd: Two times a day; qd: Once a day.